



End-of-life of nano-enabled products by thermal decomposition: Possible environmental health and safety implications

Georgios A. Sotiriou^{1,2}, Dilpreet Singh², Fang Zhang², Lutz Hoering³, Wendel Wohlleben^{2,3}, Philip Demokritou²

¹Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Stockholm, Sweden.

²Center for Nanotechnology and Nanotoxicology, Department of Environmental Health, T.H. Chan School of Public Health, Harvard University, USA. www.hsph.harvard/nano ³BASF SE, Material Physics, Germany.

email: georgios.sotiriou@ki.se

Visit our lab website: www.sotirioulab.net



Nanotoxicity: Realistic exposure scenarios?

So far: Nanotoxicity evaluation of "raw" nanomaterials, which is great for:

Life-cycle stages

Release

Fabrication of

Exposure for

Professional Users

Recycling

Exposure for

Consumers


Manufacturing

→ Mechanistic understanding

→ Occupational exposures

Realistic exposures?


 Transformations of nanomaterials during their life-cycle^[1]



[1] Nowack, David, Fissan, Morris, Shatkin, Stintz, Zepp, Brouwer. *Environ. Int.* **59**, 1 (2013). [2] Pirela, Sotiriou, Bello, Shafer, Bunker, Castranova, Thomas, Demokritou. *Nanotoxicology* **9**, 760 (2015).


Georgios A. Sotiriou 22 november 2016 2

Knowledge gaps of nano-release at End-of-Life




Our TARGET

- Obtain fundamental understanding on what factors influence the physicochemical and morphological properties of released materials
- Burning question: Is there a nanofiller-specific effect?



[1] Wohlleben, Meier, Vogel, Landsiedel, Cox, Hirth, Tomovic. Nanoscale 5, 369 (2013).

Integrated Exposure Generation System (INEXS)




Advantages


- Versatile: Easy to change thermal decomposition scenario
- Real time equipment: Monitor particle concentration, size and composition
- Collection of mg of aerosol: Allows sufficient characterization and tox studies
- In situ inhalation studies: Direct aerosol in animal chambers
- Facile collection of residual ash

NEPs panel

MARINA	F
BASF	ı
vell	P
Lowel	F
ass	E
σ	l a


	Matrix	nanofiller	nanofiller loading	application
	Polyurethane (PU)	- carbon black (CB)	- 0.1%	automotive,
		carbon nanotubes (CNT)	0.1%	buildings, textiles
	Polyethylene (PE)	- Fe₂O₃ organic filler organic filler + UV agent	- 1-5% 2% 2%	packaging, buildings, constructions
5	Polycarbonate (PC)	- CNT	- 3%	automotive, electronics
	Polypropylene (PP)	- CNT	- 3%	packaging, electronics
0111400	Ethylene vinyl acetate (EVA)	- TiO ₂	- 1-15%	packaging, biomedics
5	Medicinal waste	Ag		biomedics






Nanofiller effect on aerosol size & concentration?

Particle concentration [#/cm³]



- PU-based NEPs
 - → Pure and with two different nanofillers (carbon black-CB, and carbon nanotubes-CNTs)




- No effect on released aerosol concentration and size due to the nanofiller presence
- Host polymer dictates the released PM
- >99% organic carbon, independent of nanofiller presence

Is there any nanofiller in the released aerosol?

SEM

after dispersion in alcohol and drying on SEM substrate




PU-CNT


TEM


in-situ deposition on TEM grids in CCI

PU-CNT (800 °C)




PE-Fe₂O₃ (800 °C)






Nanofiller effect on chemistry of aerosol?


TGA-FTIR (in situ detection of off-gases), ex-situ NMR



Polycyclic aromatic hydrocarbon (PAH) species

16 Environmental Protection Agency (EPA)-priority polycyclic aromatic hydrocarbon (PAH) species








Singh et al., in preparation (2016).


with V. Craver, Univ Rhode Island


Is there nanofiller in the residual ash?












- CNTs in residual ash
- Homogeneously dispersed throughout the ash
- 18 times higher concentration than raw NEP


	500 °C		
	EC (%)	OC (%)	
PU	85	15	
PU-CB	77	23	
PU-CNT	82	18	

Effect of nanofiller on residual ash composition


 $T_{d,final} = 500^{\circ}C \text{ (PE-Fe}_2O_3)$

 Presence of Fe₂O₃ facilitates full polymer decomposiiton





	500 °C		
	EC (%)	OC (%)	
PE	78	22	
PE-org	75	25	
PE-Fe ₂ O ₃	-	-	



 Change of Fe₂O₃ crystal phase for final T = 500 °C (reduced from hematite to maghemite)

Summary

- Novel integrated exposure generation system for the end-of-life thermal decomposition of NEPs
- Main question: Is there any nanofiller-specific effect?
 - Released aerosol:
 - Not in released aerosol concentration and size
 - Yes in chemical composition
 - Residual ash:
 - Most nanofiller remains in ash
 - Physicochemical properties of remaining nanofiller might not be the same as in raw materials

Outlook

Collect and extract enough PM for tox studies (in vitro and in vivo)

Acknowledgements

HSPH

Philip Demokritou Dilpreet Singh Fang Zhang

BASF

Wendel Wohlleben Lutz Hoering

Univ Arkansas

Ilias G. Kavouras Marie-Cecile Chalbot

Carnegie Mellon

Gregory V. Lowry
Eleanor Spielman-Sun

- NSF (grant nr. 1436450)
- BASF AG
- Swiss NSF







FONDS NATIONAL SUISSE
SCHWEIZERISCHER NATIONALFONDS
FONDO NAZIONALE SVIZZERO
SWISS NATIONAL SCIENCE FOUNDATION

Thank you for listening

More info:

[1] G. A. Sotiriou, D. Singh, F. Zhang, W. Wohlleben, M-C. G. Chalbot, I. G. Kavouras & P. Demokritou*. "An integrated methodology for the assessment of environmental health implications during thermal decomposition of nano-enabled products" *Environ. Sci.: Nano* 2, 262-272 (2015).

[2] G. A. Sotiriou, D. Singh, F. Zhang, M-C. G. Chalbot, L. Hoering, I. G. Kavouras W. Wohlleben & P. Demokritou*. "Thermal decomposition of nano-enabled thermoplastics: Possible environmental health and safety implications" J. Hazard. Mater. 305, 87-95 (2016).


[3] D. Singh, G. A. Sotiriou, F. Zhang, J. Mead, D. Bello, W. Wohlleben & P. Demokritou*. "End-of-life" thermal decomposition of nano-enabled polymers: effect of nanofiller loading and polymer matrix on byproducts" Environ. Sci.: Nano in press DOI: 10.1039/C6EN00252H (2016).

Open PhD student position in our lab visit: www.sotirioulab.net for more info

sotiriou lab

16


Released aerosol concentration and size (PU-CNT)





Georgios A. Sotiriou 22 november 2016 17


NANOTOX 2012


G.A. Sotiriou, E. Diaz, M. S. Long, J. Godleski, J. Brain, S.E. Pratsinis, P. Demokritou, "A Novel Platform for Pulmonary and Cardiovascular Toxicological Characterization of Inhaled Engineered Nanomaterials", *Nanotoxicology* **6**, 680-690 (2012).






































SMALL 2013


A. Pratsinis, P. Hervella, J-C. Leroux, S.E. Pratsinis, **G.A. Sotiriou**, "Toxicity of Silver Nanoparticles in Macrophages", *Small* **9**, 2576-2584 (2013).








[3] Sotiriou, Pratsinis, Environ. Sci. Technol. 44, 5649 (2010).




















Figure S3. Dark-field images of 5.7 nm dispersed nanosilver in water and its corresponding hyperspectral image after the filtering of the acquired library.




Figure S4. Dark-field images of 16.8 nm dispersed nanosilver in water and its corresponding hyperspectral image after the filtering of the acquired library.







Figure S5. Dark-field images of the murine macrophages and the corresponding hyperspectral image after the filtering of the acquired library. No signal is detected, as expected, verifying that there is no nanosilver signal present.





ACS SUST CHEM 2013





S. Gass, J. Cohen, G. Pyrgiotakis, **G.A. Sotiriou**, S.E. Pratsinis, P. Demokritou, "Safer Formulation Concept for Flame-Generated Engineered Nanomaterials", *ACS Sustainable Chem. Eng.* **1**, 843-857 (2013).


















ES:NANO 2014


G.A. Sotiriou, C. Watson, K.M. Murdaugh, T.H. Darrah, G. Pyrgiotakis, A. Elder, J.D. Brain & P. Demokritou. "Engineering Safer-by-Design, Transparent, Silica-coated ZnO Nanorods with Reduced DNA Damage Potential", *Environ. Sci.: Nano* 1, 144-153 (2014).


























P&FT 2014

N.V. Konduru, K.M. Murdaugh, **G.A. Sotiriou**, T.C. Donaghey, P. Demokritou, J.D. Brain & R.M. Molina. "Bioavailability, distribution and clearance of tracheally-instilled and gavaged uncoated or silicacoated zinc oxide nanoparticles", *Part. Fibre Toxicol.* **11**:44 (2014).




Figure 2 Cellular and biochemical parameters of lung injury and inflammation in bronchoalveolar lavage (BAL). Tracheally instilled ZnO and SiO_2 -coated ZnO induced a dose-dependent lung injury and inflammation at 24 hours. (A) Significant increases in BAL neutrophils were observed at 1 mg/kg of both NPs (n = 6/group). At the lower dose of 0.2 mg/kg (n = 4-6/group), only the SiO_2 -coated ZnO (n = 4) induced significant neutrophil influx in the lungs. (B) Similarly, significant increases in LDH, myeloperoxidase and albumin were observed at 1 mg/kg of both NPs, and at 0.2 mg of SiO_2 -coated ZnO. (*P < 0.05, vs. control, #P < 0.05, SiO_2 -coated ZnO versus ZnO).




Figure 3 Lung clearance of 65 **Zn post-IT instillation of** 65 **ZnO and SiO**₂**-coated** 65 **ZnO NPs.** The percentages of instilled 65 **Zn** measured in the whole lungs are shown over a period of 28 days. The clearance of 65 **Zn** was rapid with only 16-18% of dose remaining at 2 days. By day 7, only 1.1% (SiO₂-coated 65 **ZnO NPs) and 1.9%** (65 **ZnO NPs) were measured in the lungs. And by the end of experiment,** 65 **Zn was nearly gone (less than 0.3% of dose). Although statistically higher levels of** 65 **ZnO NPs than of SiO**₂-coated 65 **ZnO NPs remained in the lungs at 7 and 28 days, the graphs show nearly identical clearance kinetics. (n = 8 rats at 5 minutes, 2 days, and 7 days, n = 5 at 28 days).**




Figure 4 Extrapulmonary distribution of ⁶⁵Zn post-IT instillation of ⁶⁵ZnO and SiO₂-coated ⁶⁵ZnO NPs. Data are % of instilled dose recovered in all secondary tissues examined. It included blood, thoracic lymph nodes, bone, bone marrow, skin, brain, skeletal muscle, testes, kidneys, heart, liver, and the gastrointestinal tract. There was a rapid absorption and accumulation of ⁶⁵Zn in secondary tissues. At day 2, 59-72% of the dose was detected in extrapulmonary organs. Then, ⁶⁵Zn levels decreased over time to 25-37% by day 28. Significantly more ⁶⁵Zn was detected in secondary organs at all time points in rats instilled with uncoated ⁶⁵ZnO NPs.

Table 1 Tissue distribution of ⁶⁵Zn at 2 days after intratracheal instillation of ⁶⁵ZnO or SiO₂-coated ⁶⁵ZnO NPs in rats

	ZnO	SiO ₂ -coated ZnO		⁶⁵ ZnO
	Mean ± SE	Mean ± SE		Mean ± SE
Lungs	16.08 ± 2.00	18.09 ± 2.17	Lungs	1.90 ± 0.18
Blood	2.54 ± 0.07*	2.22 ± 0.08	Blood	$2.13 \pm 0.05*$
Lymph nodes	0.63 ± 0.23	0.49 ± 0.04	Lymph nodes	0.18 ± 0.02
Bone marrow	3.37 ± 0.32	2.89 ± 0.15	Bone marrow	3.70 ± 0.28
Bone	9.59 ± 0.46	9.25 ± 0.29	Bone	12.12 ± 0.53
Skin	11.30 ± 1.00	12.52 ± 0.77	Skin	10.02 ± 0.49
Brain	0.17 ± 0.01	0.19 ± 0.01 #	Brain	0.25 ± 0.01
Skeletal muscle	14.22 ± 0.77*	6.39 ± 2.44	Skeletal muscle	19.81 ± 0.84*
Testes	0.84 ± 0.05	0.78 ± 0.04	Testes	1.27 ± 0.06
Kidneys	2.05 ± 0.07*	1.74 ± 0.03	Kidneys	0.75 ± 0.03
Spleen	0.50 ± 0.02	0.44 ± 0.02	Spleen	0.21 ± 0.01
Heart	0.47 ± 0.04 *	0.36 ± 0.01	Heart	0.27 ± 0.01*
Liver	12.23 ± 0.24*	9.88 ± 0.38	Liver	5.80 ± 0.13*
Stomach	1.01 ± 0.14	0.78 ± 0.02	Stomach	0.66 ± 0.02
Small intestine	7.37 ± 0.32	6.89 ± 0.20	Small intestine	2.83 ± 0.10
Large intestine	2.08 ± 0.21	1.91 ± 0.12	Large intestine	0.84 ± 0.07
Cecum	3.42 ± 0.22*	2.35 ± 0.25	Cecum	1.15 ± 0.06
Total recovered	87.78 ± 2.35*	76.78 ± 2.84	Total recovered	81.33 ± 6.51*

Data are mean \pm SE% instilled dose, n = 8/group. Total recovered = sum of ⁶⁵Zn in analyzed organs, feces and urine. *P < 0.05, ZnO > SiO_2 -coated ZnO. # P <0.05, SiO₂-coated ZnO > ZnO.

Table 2 Tissue distribution of ⁶⁵Zn at 7 days after intratracheal instillation of ⁶⁵ZnO or SiO₂-coated ⁶⁵ZnO NPs in rats

Nr 3 III Iacs	45	
	⁶⁵ ZnO	SiO ₂ -coated ⁶⁵ ZnO
	Mean ± SE	Mean ± SE
Lungs	1.90 ± 0.18	1.05 ± 0.04
Blood	$2.13 \pm 0.05*$	1.79 ± 0.07
Lymph nodes	0.18 ± 0.02	0.31 ± 0.05 #
Bone marrow	3.70 ± 0.28	3.38 ± 0.16
Bone	12.12 ± 0.53	12.21 ± 0.84
Skin	10.02 ± 0.49	10.55 ± 0.80
Brain	0.25 ± 0.01	0.27 ± 0.01
Skeletal muscle	19.81 ± 0.84*	8.34 ± 3.45
Testes	1.27 ± 0.06	1.23 ± 0.03
Kidneys	0.75 ± 0.03	0.69 ± 0.02
Spleen	0.21 ± 0.01	0.20 ± 0.01
Heart	$0.27 \pm 0.01*$	0.23 ± 0.01
Liver	$5.80 \pm 0.13*$	5.19 ± 0.25
Stomach	0.66 ± 0.02	0.66 ± 0.03
Small intestine	2.83 ± 0.10	2.53 ± 0.12
Large intestine	0.84 ± 0.07	0.83 ± 0.05
Cecum	1.15 ± 0.06	1.04 ± 0.09

Data are mean \pm SE% instilled dose, n = 8/group. Total recovered = sum of 65Zn in analyzed organs, feces and urine. *P < 0.05, ZnO > SiO_2 -coated ZnO. # P <0.05, SiO_2 -coated ZnO > ZnO.

 69.91 ± 3.33




Figure 5 Fecal and urinary excretion of ⁶⁵**Zn post-IT instillation of** ⁶⁵**ZnO and SiO₂-coated** ⁶⁵**ZnO NPs.** Data are estimated cumulative urinary or fecal excretion of ⁶⁵**Zn over 28 days.** The predominant excretion pathway was via the feces. Approximately half of the instilled ⁶⁵**Zn was excreted in the feces in both groups over 28 days (A).** Only about 1% of the ⁶⁵**Zn dose was excreted in the urine (B).**




Figure 6 Tissue distribution of ⁶⁵**Zn post-gavage of** ⁶⁵**ZnO and SiO₂-coated** ⁶⁵**ZnO NPs.** Data are % dose of administered ⁶⁵**Zn in different organs. (A)** At 5 minutes post-gavage, the ⁶⁵**Zn levels in tissues other than the gastrointestinal tract were much lower (0.3% for uncoated, 0.05% for coated ⁶⁵ZnO NPs). (B)** At day 7, significantly more ⁶⁵**Zn was absorbed and retained in non-GIT tissues (6.9% for uncoated, 6.0% for coated ⁶⁵ZnO NPs).** Significantly more ⁶⁵**Zn was measured in skeletal muscle in rat gavaged with uncoated versus coated ⁶⁵ZnO NPs.** (Note: RBC: red blood cell; sk muscl: skeletal muscle; sm int: small intestine: large int: large intestine).







Figure 7 Fecal and urinary excretion of ⁶⁵**Zn post-gavage of** ⁶⁵**ZnO and SiO₂-coated** ⁶⁵**ZnO NPs.** Data are estimated cumulative urinary or fecal excretion of ⁶⁵**Zn over 7 days.** Similar to the IT-instilled groups, the predominant excretion pathway was via the feces. Ninety five % of the instilled ⁶⁵**Zn was excreted in both groups by day 7 (A).** Only 0.1% of the ⁶⁵**Zn dose was excreted in the urine (B).**


ES:NANO 2015





G. A. Sotiriou, D. Singh, F. Zhang, W. Wohlleben, M-C. G. Chalbot, I. G. Kavouras & P. Demokritou. "An integrated methodology for the assessment of environmental health implications during thermal decomposition of nano-enabled products" *Environ. Sci.: Nano* **2**, 262-272 (2015).




































NANOTOXICOL OGY 2015

S. Pirela, **G.A. Sotiriou**, D. Bello, M. Shafer, K. Lee Bunker, V. Castranova, T. Thomas & P. Demokritou. "Consumer exposures to laser printer-emitted nanoparticles: A case study of the life-cycle implications from nano-enabled products" *Nanotoxicology* **9**, 760-768 (2015).















Real-time Instrumentation



P-C-M and toxicological characterization

JHAZARD MATER 2016




Table 1
Summary of all nano-enabled products (NEPs) analyzed in this study along with the main results regarding the yield, the EC/OC content as well as the Fe content for both the released aerosol and the residual ash.

NEPs				Released aerosol										Residual ash						
	Filler	Size (nm)	Loading (wt%)	500 °C						800 °C					500 ° C				800°C	
				Yield (%)		EC (%)	OC (%)	Fe (wt%)b	Yield (%)		EC(%)	OC (%)	Fe (wt%)b							
Sample ID				PM _{0.1}	PM _{0.1-2.5}				PM _{0.1}	PM _{0.1-2.5}				Yield (%)	EC (%)	OC (%)	Fe (wt%)b	Yield (%)	Fe (wt%)b	
PU	_	_	_	1.65	0.44	0.9	99.1	_	3.41	1.07	0.8	99.2	_	5.0	84.9	15.1	_	_	_	
PU-CB	CB	50-100	0.09	3.61	1.09	0.6	99.4	_	2.96	0.79	0.7	99.3	_	4.0	76.5	23.5	_	_	_	
PU-CNT	CNT	10 ^a	0.09	4.04	0.93	0.7	99.3	_	3.64 ^c	1.84	0.9	99.1 ^d	_	6.1	82.1	17.9	_	_	_	
PE	_	_	_	4.08	3.66	0.4	99.6	_	3.46	3.25	0.3	99.7	_	0.9	78.2	21.8	_	_	_	
PE-Fe ₂ O ₃	Fe_2O_3	50-100	4	2.77	0.74	0.3	99.7	0.004	1.46	1.60	0.3	99.7	0.026	3.9	_	_	74.5	3.9	77.3	
PE-org.	Org. pigm.	50-100	2	3.29	0.90	0.3	99.7	_	2.66	0.63	0.4	99.6	_	1.0	75.0	25.0	-	-	_	


PU: polyurethane, CB: carbon black, CNT: carbon nanotube, PE: polyethylene, Org: organic pigment Red 254, EC: elemental carbon, OC: organic carbon.

^a Size corresponds to diameter.

b Measured by ICP-MS.


^c Standard deviation of 3 independent measurements: 1.4%.


^d Standard deviation of 3 independent measurements: 0.2%.





Name Sumano 1-97 10/2010


77
























NANOMEDICINE 2016












Name Surname


83



Name Surname







Name Surname

88

Name Surname 14/10/2015 89

Name Surname 14/10/2015 90